MARLBOROUGH, Mass., Sept. 6, 2011 (GLOBE NEWSWIRE) -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces results from a clinical study representing the first 40 atrial fibrillation patients treated with the HeartLight EAS at Asklepios Klinik St. Georg, in Hamburg, Germany. Outcomes data demonstrating a 99% acute pulmonary vein (PV) isolation rate and a 60% chronic clinical success rate from a single catheter ablation procedure were presented at the European Society of Cardiology (ESC) Congress 2011, in Paris, France.
